Disopyramide Phosphate and Patiromer Sorbitex Calcium
Determining the interaction of Disopyramide Phosphate and Patiromer Sorbitex Calcium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Disopyramide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential. MANAGEMENT: Coadministration of disopyramide with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with disopyramide. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope. References "Multum Information Services, Inc. Expert Review Panel" Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:GENERALLY AVOID: Disopyramide can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.
MANAGEMENT: Coadministration of disopyramide with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with disopyramide. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.
- "Multum Information Services, Inc. Expert Review Panel"
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: disopyramide
Brand name: Norpace, Norpace CR
Synonyms: Disopyramide
Generic Name: patiromer
Brand name: Veltassa
Synonyms: Patiromer
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Disopyramide Phosphate-Pavacot
- Disopyramide Phosphate-Paxil
- Disopyramide Phosphate-Paxil (Paroxetine Suspension)
- Disopyramide Phosphate-Paxil (Paroxetine Tablets)
- Disopyramide Phosphate-Paxil CR
- Disopyramide Phosphate-Pazopanib
- Patiromer Sorbitex Calcium-Disopyramide Sustained-Release Capsules
- Patiromer Sorbitex Calcium-DisperMox
- Patiromer Sorbitex Calcium-Disposable Enema rectal
- Patiromer Sorbitex Calcium-Disulfiram
- Patiromer Sorbitex Calcium-Dithol Solution
- Patiromer Sorbitex Calcium-Ditropan